| 8.49 -0.25 (-2.86%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.91 | 1-year : | 11.87 |
| Resists | First : | 9.34 | Second : | 10.17 |
| Pivot price | 8.59 |
|||
| Supports | First : | 8 | Second : | 6.65 |
| MAs | MA(5) : | 8.7 |
MA(20) : | 8.68 |
| MA(100) : | 11.42 |
MA(250) : | 11.77 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.6 |
| %K %D | K(14,3) : | 53.2 |
D(3) : | 58 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 15.85 | Low : | 8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BNTC ] has closed above bottom band by 38.2%. Bollinger Bands are 59.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.93 - 8.97 | 8.97 - 9.01 |
| Low: | 8.33 - 8.37 | 8.37 - 8.41 |
| Close: | 8.66 - 8.74 | 8.74 - 8.81 |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Sat, 31 Oct 2026
Benitec Biopharma Inc. (BNTC) Seasonal returns chart - Yahoo Finance Australia
Fri, 30 Oct 2026
Benitec Biopharma Limited (BNTC) Seasonal returns chart - Yahoo Finance UK
Wed, 28 Oct 2026
Benitec Biopharma (BNTC) Reports Promising Interim Results for B - GuruFocus
Wed, 28 Oct 2026
Benitec Biopharma Announces Encouraging Interim Phase 1b/2a Results for BB-301 - Kalkine Media
Wed, 28 Oct 2026
Every patient in Benitec’s study responded to an experimental treatment for a disease that weakens swallowing. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 96 (%) |
| Shares Short | 2,040 (K) |
| Shares Short P.Month | 2,210 (K) |
| EPS | -0.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.13 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.7 % |
| Return on Equity (ttm) | -33.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -8.67 |
| PEG Ratio | 0 |
| Price to Book value | 1.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.94 |
| Dividend | 0.75 |
| Forward Dividend | 0 |
| Dividend Yield | 8.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|